The Clinicopathological and Prognostic Values of Chemotherapy Response Score in Tubo-Ovarian High-Grade Serous Carcinoma

Tubo-ovarian high-grade serous carcinoma is one of the aggressive ovarian tumors. Neoadjuvant chemotherapy has been used in managing the affected patients. The chemotherapy response score (CRS) system has been introduced to evaluate the patient’s response to neoadjuvant chemotherapy and their prognosis. The current study aimed to investigate the prognostic and clinicopathological significance of the CRS system in patients with tubo-ovarian high-grade serous carcinoma.

A total of 39 patients with tubo-ovarian high-grade serous carcinoma were included in the current study. We retrospectively investigated the progression-free survival (PFS), overall survival (OS), and their clinicopathological and surgical parameters. We also studied the Ki67 protein expression of included patients using immunohistochemistry (IHC). Besides, we investigated the significance of Ki67 expression in tubo-ovarian high-grade serous carcinoma development using the GSE73064 and GSE126308 datasets.

Ki67 expression was not alerted in ascites, metastatic, and primary tubo-ovarian high-grade serous carcinoma. Also, Ki67 expression was not changed in the early tubo-ovarian high-grade serous carcinoma compared to late tubo-ovarian high-grade serous carcinoma. We showed that Ki67 protein expression was elevated in CRS1 patients with tubo-ovarian high-grade serous carcinoma compared to CRS3 patients. The bleeding amount and operation time were substantially lower in CRS3 patients compared to CRS1 patients, and there was a strong positive association between CRS3 and optimal resection. Furthermore, CRS3 patients had substantially improved PFS compared to CRS1 patients.

This study has highlighted the valuable role of the CRS system in determining the PFS and some clinicopathological features of tubo-ovarian high-grade serous carcinoma patients.